

	n=19 WHOLE TREATED COHORT		n=11 ALLO-SCT		n=8 MAINTENANCE		P	n=6 NO UPFRONT TREATMENT		p
Variable	n or median	% or IQR	n or median	% or IQR	n or median	% or IQR		n or median	% or IQR	
Male	6	31.60%	3	27.30%	3	37.5%	1	3	50.0%	0.7693
Age at CAR T-cell infusion	7.9 years	6.1-12.6	7.9	6.3-12.8	8.75	4.9-12.2	0.8043	13.4	9.8-19.7	0.1974
Characteristics of initial diagnosis										
Infant ALL (n of pts)	3	15.80%	1	9.10%	2	25%	0.5459	0	0.0%	0.4357
Median WCC (x 10 ⁹ /L)	10	9.4-99.8	10	9.9-44	40	8.5-128.5	0.8729	36.5	19.1-51.8	0.9297
NCI risk										
High	7	36.80%	2	27.30%	4	50%	0.37	1	16.7%	0.8212
Standard	9	47.40%	7	54.50%	3	37.50%		3	50.0%	
Not known	3	15.80%	2	18.20%	1	12.50%		2	33.3%	
Cytogenetic risk										
Good risk	9	47.40%	5	45.50%	4	50%	1	1	16.7%	0.1978
<i>ETV6-RUNX1</i>	3	15.80%	2	18.20%	1	12.50%		1	16.7%	
High hyperdiploid	6	31.60%	3	27.30%	3	37.50%				
Intermediate risk	1	5.30%	1	9.10%	0					
IKZF1 deletion	1	5.30%	1	9.10%	0					
High risk	5	26.30%	3	27.30%	2	25%		0	0%	
<i>KMT2Ar</i>	3	15.80%	1	9.10%	2	25%				
<i>BCR-ABL</i>	1	5.30%	1	9.10%	0					
t(17;19)/ <i>TCF3-HLF</i>	1	5.30%	1	9.10%	0					
Uninformative cytogenetics	4	21.10%	2	18.20%	2	25%		5	83.3%	
Unknown	1	5.30%	1	9.10%	0			1	16.7%	
Other	3	15.80%	1	9.10%	2	25%		4	66.7%	
Characteristics of relapsed/refractory disease										

Indication for CAR T										
Primary refractory	1	5.30%	1	9.10%	0		1	0	0.0%	1
Relapse	18	94.70%	10	90.90%	8	100%		6	100.0%	
Refractory status										
At any time point	11	57.90%	7	63.60%	4	50%	0.6577	1	16.7%	0.2399
Median number of relapses	1	1.0-2.0	1	1.0-1.5	1.5	1.0-2.0	0.2754	2	2.0-2.8	0.0359
CNS and extramedullary disease										
CNS at any point	11	57.90%	5	45.50%	6	75%	0.3521	2	33.3%	0.3426
EM non-CNS relapses (both isolated and combined)	2	10.50%	1	9.10%	1	12.50%	1	2	50.0%	0.5235
Median number of previous therapy lines (excluding SCT)	2	2.0-2.0	2	2.0-2.0	2	2.0-2.2	0.7737	2	2.0-2.75	0.5282
Prior SCT	5	26.30%	2	18.20%	3	37.50%	0.6027	3	50.0%	0.4199
Blinatumomab exposure	4	21.10%	1	9.10%	3	37.50%	0.2621	1	16.7%	0.3789
Inotuzumab exposure	1	5.30%	0		1	12.50%	0.4211	2	33.3%	0.08522
CAR T-cell therapy										
Status pre-lymphodepletion										
High disease burden (>=5%)	3	15.80%	2	18.20%	1	12.50%	1	4	66.7%	0.09322
Low disease burden (<5%)	11	57.90%	6	54.60%	5	62.50%		0		
Undetectable by MRD	5	26.30%	3	27.30%	2	25%		2	50.0%	
CAR T-cell product										
Tisagenlecleucel	17	89.50%	10	90.90%	7	87.50%	1	4	66.7%	0.5235
Experimental	2	10.50%	1	9.10%	1	12.50%		2	33.3%	
Median CAR T-cell dose/kg (n=17)	2.7x10 ⁶ /kg	1.8-3.7 7x10 ⁶ /kg	3.4 7x10 ⁶ /kg	2.5-4.3 7x10 ⁶ /kg	2.4 7x10 ⁶ /kg	1.5- 2.87x10 ⁶ / kg	0.2069	2 7x10 ⁶ /kg	1.6-2.95 7x10 ⁶ /kg	0.4019
Time to LBCA										
Median (months)	2.66 months	95% CI: 2.3- 3.6	2.66	95% CI: 2.07 to not reachde	2.64	95% CI: 2.3 to not reached	0.9	2.59	95% CI: 1.61 to not reached	1

0-3 months	13	68.4%	7	63.60%	6	75%	1	4	66.7%	1
3-6 months	6	31.60%	4	34.4%	2	25%		2	50.0%	

Supplementary Table

Including patients (n = 6 who did not receive treatment for early LBCA).

Categorical variables are compared with Fisher exact test, continuous variables with Kruskal-Wallis test.